Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 190


Interval lung cancers not detected on screening chest X-rays: How are they different?

Kvale PA, Johnson CC, Tammemägi M, Marcus PM, Zylak CJ, Spizarny DL, Hocking W, Oken M, Commins J, Ragard L, Hu P, Berg C, Prorok P.

Lung Cancer. 2014 Oct;86(1):41-6. doi: 10.1016/j.lungcan.2014.07.013. Epub 2014 Jul 24.


Diagnostic evaluation following a positive lung screening chest radiograph in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial.

Hocking WG, Tammemagi MC, Commins J, Oken MM, Kvale PA, Hu P, Ragard LR, Riley TL, Pinsky P, Beck TM, Prorok PC.

Lung Cancer. 2013 Nov;82(2):238-44. doi: 10.1016/j.lungcan.2013.07.017. Epub 2013 Aug 7.


Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.

Vesole DH, Oken MM, Heckler C, Greipp PR, Katz MS, Jacobus S, Morrow GR; University of Rochester Cancer Center and the Eastern Cooperative Oncology Group.

Leukemia. 2012 Dec;26(12):2517-20. doi: 10.1038/leu.2012.124. Epub 2012 May 8.


Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan JK, Berg CD; PLCO Project Team.

JAMA. 2011 Nov 2;306(17):1865-73. doi: 10.1001/jama.2011.1591. Epub 2011 Oct 26.


Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.

Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, Riley TL, Commins J, Oken MM, Berg CD, Prorok PC.

J Natl Cancer Inst. 2011 Jul 6;103(13):1058-68. doi: 10.1093/jnci/djr173. Epub 2011 May 23.


Dietary factors and risk of chronic lymphocytic leukemia and small lymphocytic lymphoma: a pooled analysis of two prospective studies.

Tsai HT, Cross AJ, Graubard BI, Oken M, Schatzkin A, Caporaso NE.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2680-4. doi: 10.1158/1055-9965.EPI-10-0585.


Associations between anthropometry, cigarette smoking, alcohol consumption, and non-Hodgkin lymphoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Troy JD, Hartge P, Weissfeld JL, Oken MM, Colditz GA, Mechanic LE, Morton LM.

Am J Epidemiol. 2010 Jun 15;171(12):1270-81. doi: 10.1093/aje/kwq085. Epub 2010 May 21.


Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Hocking WG, Hu P, Oken MM, Winslow SD, Kvale PA, Prorok PC, Ragard LR, Commins J, Lynch DA, Andriole GL, Buys SS, Fouad MN, Fuhrman CR, Isaacs C, Yokochi LA, Riley TL, Pinsky PF, Gohagan JK, Berg CD; PLCO Project Team.

J Natl Cancer Inst. 2010 May 19;102(10):722-31. doi: 10.1093/jnci/djq126. Epub 2010 May 4.


Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk.

Church TR, Haznadar M, Geisser MS, Anderson KE, Caporaso NE, Le C, Abdullah SB, Hecht SS, Oken MM, Van Ness B.

Int J Mol Epidemiol Genet. 2010 Aug 5;1(4):295-309.


A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma.

Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, Mirabello L, Jacobs K, Wheeler W, Yeager M, Bergen AW, Li Q, Consonni D, Pesatori AC, Wacholder S, Thun M, Diver R, Oken M, Virtamo J, Albanes D, Wang Z, Burdette L, Doheny KF, Pugh EW, Laurie C, Brennan P, Hung R, Gaborieau V, McKay JD, Lathrop M, McLaughlin J, Wang Y, Tsao MS, Spitz MR, Wang Y, Krokan H, Vatten L, Skorpen F, Arnesen E, Benhamou S, Bouchard C, Metspalu A, Vooder T, Nelis M, Välk K, Field JK, Chen C, Goodman G, Sulem P, Thorleifsson G, Rafnar T, Eisen T, Sauter W, Rosenberger A, Bickeböller H, Risch A, Chang-Claude J, Wichmann HE, Stefansson K, Houlston R, Amos CI, Fraumeni JF Jr, Savage SA, Bertazzi PA, Tucker MA, Chanock S, Caporaso NE.

Am J Hum Genet. 2009 Nov;85(5):679-91. doi: 10.1016/j.ajhg.2009.09.012. Epub 2009 Oct 15. Erratum in: Am J Hum Genet. 2011 Jun 10;88(6):861. Metsapalu, Andres [corrected to Metspalu, Andres].


A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.

Purdue MP, Lan Q, Martinez-Maza O, Oken MM, Hocking W, Huang WY, Baris D, Conde B, Rothman N.

Blood. 2009 Sep 24;114(13):2730-2. doi: 10.1182/blood-2009-04-217521. Epub 2009 Jul 28.


Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.

Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, Prchal J, Peterson BA; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group.

Leuk Lymphoma. 2009 Oct;50(10):1606-17. doi: 10.1080/10428190903093807.


Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study.

Tammemagi MC, Freedman MT, Pinsky PF, Oken MM, Hu P, Riley TL, Ragard LR, Berg CD, Prorok PC.

J Thorac Oncol. 2009 Jun;4(6):710-21. doi: 10.1097/JTO.0b013e31819e77ce.


Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma.

Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jagannath S.

Leuk Lymphoma. 2009 Apr;50(4):559-65. doi: 10.1080/10428190902748971.


Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival.

Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D, Morgan G.

BMC Med. 2008 Sep 8;6:26. doi: 10.1186/1741-7015-6-26.


Clinical and biological significance of RAS mutations in multiple myeloma.

Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, Kyle RA, Henderson KJ, Van Wier S, Greipp P, Van Ness B, Fonseca R.

Leukemia. 2008 Dec;22(12):2280-4. doi: 10.1038/leu.2008.142. Epub 2008 Jun 5. No abstract available.


Appraisal of immunoglobulin free light chain as a marker of response.

Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, Henderson K, Kyle RA, Oken MM, Bradwell AR, Greipp PR.

Blood. 2008 May 15;111(10):4908-15. doi: 10.1182/blood-2008-02-138602. Epub 2008 Mar 25.


Factors associated with human small aggressive non small cell lung cancer.

Tammemagi CM, Freedman MT, Church TR, Oken MM, Hocking WG, Kvale PA, Hu P, Riley TL, Ragard LR, Prorok PC, Berg CD.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2082-9.


Multiple myeloma: a review of the epidemiologic literature.

Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, Trichopoulos D.

Int J Cancer. 2007;120 Suppl 12:40-61. Review.


Prevalence of non-cancer-related abnormalities on low-dose spiral computer tomography versus chest radiograph in a screening population.

Pinsky P, Freedman M, Oken M, Kvale P, Caporaso N, Gohagan J.

Thorax. 2007 Feb;62(2):190. No abstract available.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk